Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,950 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: shepherd j. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Safety of rosuvastatin.
Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG. Shepherd J, et al. Am J Cardiol. 2004 Oct 1;94(7):882-8. doi: 10.1016/j.amjcard.2004.06.049. Am J Cardiol. 2004. PMID: 15464670 Clinical Trial.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Deedwania P, et al. Among authors: shepherd j. Lancet. 2006 Sep 9;368(9539):919-28. doi: 10.1016/S0140-6736(06)69292-1. Lancet. 2006. PMID: 16962881 Clinical Trial.
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Ford I, et al. Among authors: shepherd j. N Engl J Med. 2007 Oct 11;357(15):1477-86. doi: 10.1056/NEJMoa065994. N Engl J Med. 2007. PMID: 17928595 Free article. Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Shepherd J, et al. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. doi: 10.2215/CJN.04371206. Epub 2007 Oct 17. Clin J Am Soc Nephrol. 2007. PMID: 17942759 Clinical Trial.
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Ridker PM, et al. Among authors: shepherd j. Am J Cardiol. 2007 Dec 1;100(11):1659-64. doi: 10.1016/j.amjcard.2007.09.072. Epub 2007 Oct 24. Am J Cardiol. 2007. PMID: 18036365 Clinical Trial.
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Shepherd J, et al. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072. J Am Coll Cardiol. 2008. PMID: 18402899 Free article. Clinical Trial.
2,950 results